Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

20 maj 2019 uppdaterad av: Novartis Pharmaceuticals

A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis

This study was designed as a 3-year extension to the phase III core study CAIN457F2306. It aimed to provide continuous treatment with secukinumab in pre-filled syringes (PFS) for subjects who completed the core study CAIN457F2306, to obtain further long term efficacy, safety and tolerability information in subjects with active psoriatic arthritis receiving secukinumab every 4 weeks. At Week 104 of the study CAIN457F2306, eligible subjects completed the assessments associated with the core study visit and subsequently continued in this extension study on the same dose that they were receiving during the core study. The regular assessments of disease activity ensure that subjects who are experienced worsening of disease in any of the treatment groups could exit the study upon their own wish or based on the advice of the investigator at any time.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

460

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Argentina
      • Buenos Aires, Argentina, C1417EYG
        • Novartis Investigative Site
      • Caba, Argentina, C1419AHN
        • Novartis Investigative Site
      • Cordoba, Argentina, X5016KEH
        • Novartis Investigative Site
      • Córdoba, Argentina, X5000EDC
        • Novartis Investigative Site
    • Buenos Aires
      • Caba, Buenos Aires, Argentina, C1181ACH
        • Novartis Investigative Site
    • Santa Fe
      • Rosario, Santa Fe, Argentina, S2000CFJ
        • Novartis Investigative Site
  • Australien
    • Queensland
      • Maroochydore, Queensland, Australien, 4558
        • Novartis Investigative Site
    • Victoria
      • Malvern East, Victoria, Australien, 3145
        • Novartis Investigative Site
  • Belgien
      • Genk, Belgien, 3600
        • Novartis Investigative Site
      • Gent, Belgien, 9000
        • Novartis Investigative Site
      • Leuven, Belgien, 3000
        • Novartis Investigative Site
  • Brasilien
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brasilien, 90610-000
        • Novartis Investigative Site
    • SP
      • Sao Paulo, SP, Brasilien, 04023-900
        • Novartis Investigative Site
      • Sao Paulo, SP, Brasilien, 04266 010
        • Novartis Investigative Site
  • Bulgarien
      • Pleven, Bulgarien, 5800
        • Novartis Investigative Site
      • Sofia, Bulgarien, 1612
        • Novartis Investigative Site
    • Gabrovo
      • Sevlievo, Gabrovo, Bulgarien, 5400
        • Novartis Investigative Site
  • Filippinerna
      • Las Pinas, Filippinerna, 1740
        • Novartis Investigative Site
      • Manila, Filippinerna, 1003
        • Novartis Investigative Site
      • Manila, Filippinerna, 1008
        • Novartis Investigative Site
      • Quezon City, Filippinerna, 1102
        • Novartis Investigative Site
      • Quezon City, Filippinerna, 1118
        • Novartis Investigative Site
    • Batangas
      • Lipa City, Batangas, Filippinerna, 4217
        • Novartis Investigative Site
    • Cavite
      • Dasmarinas, Cavite, Filippinerna, 4114
        • Novartis Investigative Site
    • Metro Manila
      • Manila, Metro Manila, Filippinerna, 1003
        • Novartis Investigative Site
  • Förenta staterna
    • Alabama
      • Anniston, Alabama, Förenta staterna, 36207-5710
        • Novartis Investigative Site
    • Arizona
      • Mesa, Arizona, Förenta staterna, 85202
        • Novartis Investigative Site
      • Paradise Valley, Arizona, Förenta staterna, 85253
        • Novartis Investigative Site
    • California
      • Upland, California, Förenta staterna, 91786
        • Novartis Investigative Site
    • Florida
      • Tamarac, Florida, Förenta staterna, 33321
        • Novartis Investigative Site
    • Minnesota
      • Eagan, Minnesota, Förenta staterna, 55121
        • Novartis Investigative Site
    • Missouri
      • Saint Louis, Missouri, Förenta staterna, 63117
        • Novartis Investigative Site
    • Nebraska
      • Lincoln, Nebraska, Förenta staterna, 68516
        • Novartis Investigative Site
    • New Jersey
      • Freehold, New Jersey, Förenta staterna, 07728
        • Novartis Investigative Site
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28210
        • Novartis Investigative Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73103
        • Novartis Investigative Site
    • Pennsylvania
      • Duncansville, Pennsylvania, Förenta staterna, 16635
        • Novartis Investigative Site
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29460
        • Novartis Investigative Site
      • Columbia, South Carolina, Förenta staterna, 29204
        • Novartis Investigative Site
    • Tennessee
      • Jackson, Tennessee, Förenta staterna, 38305
        • Novartis Investigative Site
    • Texas
      • Benbrook, Texas, Förenta staterna, 76126
        • Novartis Investigative Site
      • Dallas, Texas, Förenta staterna, 75216
        • Novartis Investigative Site
      • Dallas, Texas, Förenta staterna, 75246
        • Novartis Investigative Site
      • Houston, Texas, Förenta staterna, 77074
        • Novartis Investigative Site
      • League City, Texas, Förenta staterna, 77573
        • Novartis Investigative Site
      • Mesquite, Texas, Förenta staterna, 75150
        • Novartis Investigative Site
    • Washington
      • Seattle, Washington, Förenta staterna, 98122
        • Novartis Investigative Site
  • Israel
      • Ashkelon, Israel, 78278
        • Novartis Investigative Site
      • Haifa, Israel, 3339419
        • Novartis Investigative Site
      • Ramat Gan, Israel, 5265601
        • Novartis Investigative Site
      • Tel Aviv, Israel, 6423906
        • Novartis Investigative Site
  • Italien
    • CT
      • Catania, CT, Italien, 95100
        • Novartis Investigative Site
    • PO
      • Prato, PO, Italien, 59100
        • Novartis Investigative Site
    • SI
      • Siena, SI, Italien, 53100
        • Novartis Investigative Site
    • VR
      • Verona, VR, Italien, 37134
        • Novartis Investigative Site
  • Kanada
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1C 5B8
        • Novartis Investigative Site
      • St. John's, Newfoundland and Labrador, Kanada, A1A 5E8
        • Novartis Investigative Site
    • Ontario
      • Newmarket, Ontario, Kanada, L3Y 3R7
        • Novartis Investigative Site
      • Waterloo, Ontario, Kanada, N2J 1C4
        • Novartis Investigative Site
    • Quebec
      • Trois-Rivieres, Quebec, Kanada, G8Z 1Y2
        • Novartis Investigative Site
  • Polen
      • Bialystok, Polen, 15-351
        • Novartis Investigative Site
      • Warszawa, Polen, 02-341
        • Novartis Investigative Site
  • Ryska Federationen
      • Ekaterinburg, Ryska Federationen, 620109
        • Novartis Investigative Site
      • Ekaterinburg, Ryska Federationen, 620028
        • Novartis Investigative Site
      • Kemerovo, Ryska Federationen, 650029
        • Novartis Investigative Site
      • Moscow, Ryska Federationen, 115522
        • Novartis Investigative Site
      • St Petersburg, Ryska Federationen, 190068
        • Novartis Investigative Site
      • Yaroslavl, Ryska Federationen, 150003
        • Novartis Investigative Site
  • Singapore
      • Singapore, Singapore, 119074
        • Novartis Investigative Site
      • Singapore, Singapore, 529889
        • Novartis Investigative Site
      • Singapore, Singapore, 169608
        • Novartis Investigative Site
  • Slovakien
      • Lucenec, Slovakien, 984 01
        • Novartis Investigative Site
  • Storbritannien
      • Glasgow, Storbritannien, G31 2ER
        • Novartis Investigative Site
      • London, Storbritannien, SE1 9RT
        • Novartis Investigative Site
    • London
      • Leytonstone, London, Storbritannien, E11 1NR
        • Novartis Investigative Site
    • Staffordshire
      • Cannock, Staffordshire, Storbritannien, WS11 2XY
        • Novartis Investigative Site
    • West Yorkshire
      • Bradford, West Yorkshire, Storbritannien, BD5 0NA
        • Novartis Investigative Site
  • Thailand
      • Bangkok, Thailand, 10400
        • Novartis Investigative Site
      • Chiang Mai, Thailand, 50200
        • Novartis Investigative Site
    • THA
      • Khon Kaen, THA, Thailand, 40002
        • Novartis Investigative Site
  • Tjeckien
    • Czech Republic
      • Bruntal, Czech Republic, Tjeckien, 792 01
        • Novartis Investigative Site
      • Uherske Hradiste, Czech Republic, Tjeckien, 686 01
        • Novartis Investigative Site
      • Zlin, Czech Republic, Tjeckien, 760 01
        • Novartis Investigative Site
  • Tyskland
      • Aachen, Tyskland, 52064
        • Novartis Investigative Site
      • Erlangen, Tyskland, 91054
        • Novartis Investigative Site
      • Erlangen, Tyskland, 91056
        • Novartis Investigative Site
      • Gommern, Tyskland, 39245
        • Novartis Investigative Site
      • Hamburg, Tyskland, 22415
        • Novartis Investigative Site
      • Hildesheim, Tyskland, 31134
        • Novartis Investigative Site
      • Koeln, Tyskland, 50937
        • Novartis Investigative Site
      • Leipzig, Tyskland, 04103
        • Novartis Investigative Site
      • Nürnberg, Tyskland, 90429
        • Novartis Investigative Site
      • Ratingen, Tyskland, 40878
        • Novartis Investigative Site
      • Zerbst, Tyskland, 39261
        • Novartis Investigative Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria

  • Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed
  • Subjects must have participated in core study CAIN457F2306, and must have completed the entire treatment period
  • Subjects must be deemed by the investigator to benefit from continued secukinumab therapy

Exclusion criteria

  • Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab
  • Any subject who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., 20 weeks in EU)

Other protocol-defined inclusion/exclusion criteria may apply

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Secukinumab 75mg
Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
Läkemedel: Secukinumab
Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Andra namn:
  • AIN457
Experimentell: Secukinumab 150mg
Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
Läkemedel: Secukinumab
Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Andra namn:
  • AIN457
Experimentell: Placebo - AIN457A 75mg
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
Läkemedel: Placebo
Placebo
Andra namn:
  • Placebo - AIN457A
Läkemedel: Secukinumab
Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Andra namn:
  • AIN457
Experimentell: Placebo - AIN457 150mg
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
Läkemedel: Placebo
Placebo
Andra namn:
  • Placebo - AIN457A
Läkemedel: Secukinumab
Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Andra namn:
  • AIN457

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260

Proportion of subjects with a positive clinical response to treatment (individual improvement) in disease activity according to ACR20 criteria if he/she has at least 20% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:

  • Patient's assessment of Psoriatic Arthritis (PsA) pain
  • Patient's global assessment of disease activity
  • Physician's global assessment of disease activity
  • Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
  • Acute phase reactant (hsCRP or ESR)
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Proportion of Subjects Who Reached ACR50
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260

Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR50 criteria if he/she has at least 50% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:

  • Patient's assessment of PsA pain
  • Patient's global assessment of disease activity
  • Physician's global assessment of disease activity
  • Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
  • Acute phase reactant (hsCRP or ESR)
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Proportion of Subjects Who Reached ACR70
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260

Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR70 criteria if he/she has at least 70% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:- Patient's assessment of PsA pain

  • Patient's global assessment of disease activity
  • Physician's global assessment of disease activity
  • Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score)
  • Acute phase reactant (hsCRP or ESR)
weeks 116, 128, 140, 156, 180, 208, 232 and 260

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260

Changes from baseline in score of the disability assessment component of the HAQ (Health Assessment Questionnaire - Disability Index). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.

Health Assessment Questionnaire - Disability Index (HAQ-DI) ranges from 0 (no disability) to 3 (very severe disability)
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260
Percentage of subjects with improvements from baseline in HAQ-DI meeting or exceeding minimal clinically important difference (MCID=0.3). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Change From Baseline in Disease Activity Score-CRP (DAS28)
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260

Changes in DAS28 (utilizing hsCRP) from baseline up to Month 60. The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. This measure represents change in scores - not the actual scores.

DAS28 is a combined measure of disease activity based on the following formula:

DAS28-CRP = 0.56*TJC28^0.5 + 0.28*SJC28^0.5 + 0.36*ln(CRP+1) + 0.014*PGA + 0.96 The greater the score is, the more the disease activity exists. Remission is defined as DAS28-CRP < 2.6 Low disease activity is defined as DAS28-CRP < 3.2 The minimum value can be 0.96 (not applicable in our study due to the inclusion/exclusion criteria regarding tender, swollen joints). There is no maximum expected value for this score
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Percentage of Subjects Achieving Low Disease Activity
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260
Percentage of subjects achieving low disease activity (DAS28 ≤ 3.2). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Percentage of Subjects Achieving Disease Remission (DAS28<2.6)
Tidsram: weeks 116, 128, 140, 156, 180, 208, 232 and 260
Percentage of subjects achieving disease remission (DAS28<2.6). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission
weeks 116, 128, 140, 156, 180, 208, 232 and 260

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Novartis Pharmaceuticals

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 september 2013

Primärt slutförande (Faktisk)

11 januari 2018

Avslutad studie (Faktisk)

11 januari 2018

Studieregistreringsdatum

Först inskickad

1 juli 2013

Först inskickad som uppfyllde QC-kriterierna

1 juli 2013

Första postat (Uppskatta)

4 juli 2013

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 juni 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 maj 2019

Senast verifierad

1 maj 2019

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CAIN457F2306E1
  • 2013-001241-13 (EudraCT-nummer)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

IPD-planbeskrivning

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera